Cardiometabolic
Metabolic syndrome may leave a signature in mitochondrial DNA. The biomarker race should not outrun the evidence
A small pilot study has linked mitochondrial DNA variation in blood monocytes with vascular stenosis, glucose, insulin, cholesterol and inflammatory activity in people with obesity and metabolic syndrome. The findings point toward a more personalised understanding of cardiometabolic disease, but they are nowhere near ready to become a diagnostic test.
AI Diabetes Tools Need Infrastructure Before Scale
Diabetes Tech Moves From Optional Add-On to Earlier Care
Obesity Care Starts Moving Beyond BMI
Canada’s Generic Semaglutide Approval Tests GLP-1 Affordability
India’s Obesity Campaign Dispute Tests the Line Between Awareness and Promotion
England’s Tirzepatide Rollout Shows Approval Is Not Access
Medicare’s GLP-1 Bridge Turns Obesity Coverage Into a Public-Payer Experiment
WHO Makes Obesity Treatment a Global Access Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.